Related Experiment Video
Updated: Oct 27, 2025
06:03
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
1.0K
OXALIPLATIN INDUCED PULMONARY FIBROSIS: A CASE REPORT
Mirjana Pavlović1, Robert Šeparović1, Tajana Silovski1
1Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Medical Oncology, Zagreb, Croatia.
Acta Clinica Croatica
|July 21, 2021
Summary
Oxaliplatin chemotherapy can cause rare but fatal pulmonary fibrosis in colorectal cancer patients. Early diagnosis and corticosteroid treatment are vital for improving outcomes in these serious cases.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Oxaliplatin is a key component of chemotherapy for colorectal carcinoma.
- Pulmonary fibrosis is a rare but severe adverse event associated with oxaliplatin.
- This side effect has a high mortality rate, exceeding 50% in reported cases.
Observation:
- A case of pulmonary fibrosis occurred in a patient undergoing the FOLFOX regimen for early colorectal carcinoma.
- The exact mechanism causing oxaliplatin-induced pulmonary fibrosis remains unclear.
- Clinical data suggest a link between the FOLFOX regimen and this adverse event.
Findings:
- Early identification of pulmonary fibrosis is critical for patient prognosis.
- Prompt initiation of corticosteroid therapy appears to be essential for managing this condition.
- The reported case highlights the potential for severe pulmonary complications even in early-stage disease.
Implications:
- This case underscores the importance of vigilant monitoring for pulmonary toxicity in patients receiving oxaliplatin.
- Further research into the pathophysiology of oxaliplatin-induced pulmonary fibrosis is warranted.
- Clinical guidelines may need to incorporate earlier diagnostic and therapeutic strategies for suspected cases.
